Sort by
Refine Your Search
-
regeneration fails. We use a multidisciplinary approach that involves stem cell biology, systems biology, computational biology, molecular engineering and mouse models of disease. The current project will use in
-
have previous experience in immunological research, mouse handling and computational biology It is a merit if the applicant has some experience with flow cytometry analysis and cell sorting as
-
adapting work plans aligned with the project objectives, designing and conducting both wet lab and computational experiments, and analysing results. Regular discussions with supervisors and team members
-
vaccination and contribute to novel treatments and diagnostic methods. The project take advantage of methods for cell biology, molecular biology, and virology, including advanced flow cytometry. Experiments
-
laboratory animal science (FELASA B) Experience in working with laboratory mice (e.g. basic handling, intracerebral injections) Experience in computational data analysis (e.g. R or Python) Terms and conditions
-
environment with access to world-class facilities and expertise in developmental biology, genetics, and computational analysis. The ERC highlighted the project as an example of funded research, for more details
-
Reviews Drug Discovery 2015). More specifically, the group focuses its work around understanding basic biology and how to genetically engineer NK cells to improve their in vivo persistence and homing
-
to maintaining a friendly and productive work environment. Applicants are required to: Have a deep interest in computational medicine research and possess a master’s degree in computational biology, Bioinformatics
-
responsible to follow the general rules and regulations and time plan of the doctoral program. What do we offer? A creative and inspiring environment full of expertise and curiosity. Karolinska Institutet is
-
against infectious diseases. The team is interdisciplinary, comprising biologists, and computational biologists who collaborate to explore cutting-edge questions in B-cell immunology and malignancy. We